X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1569) 1569
Publication (163) 163
Newsletter (72) 72
Book Review (15) 15
Book Chapter (8) 8
Magazine Article (2) 2
Newspaper Article (2) 2
Book / eBook (1) 1
Conference Proceeding (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1075) 1075
mucopolysaccharidosis (798) 798
index medicus (740) 740
genetics & heredity (556) 556
male (523) 523
female (487) 487
animals (446) 446
enzymes (414) 414
enzyme replacement therapy (380) 380
medicine, research & experimental (369) 369
child (351) 351
glycosaminoglycans (307) 307
child, preschool (292) 292
mice (266) 266
endocrinology & metabolism (262) 262
disease (250) 250
adolescent (246) 246
pediatrics (230) 230
adult (217) 217
glycosaminoglycans - metabolism (205) 205
analysis (202) 202
infant (191) 191
biochemistry & molecular biology (177) 177
care and treatment (172) 172
disease models, animal (172) 172
children (167) 167
health aspects (164) 164
research (158) 158
lysosomal storage diseases (156) 156
bone-marrow-transplantation (155) 155
diagnosis (155) 155
mutation (146) 146
transplantation (145) 145
medicine (140) 140
enzyme-replacement therapy (139) 139
mucopolysaccharidosis ii - genetics (138) 138
mouse model (131) 131
genetics (128) 128
medicine & public health (128) 128
lysosomal storage disease (127) 127
sulfates (124) 124
gene therapy (119) 119
glycosaminoglycans - urine (119) 119
internal medicine (119) 119
phenotype (119) 119
article (115) 115
biochemistry, general (113) 113
cells, cultured (113) 113
mucopolysaccharidoses (111) 111
metabolic diseases (106) 106
treatment outcome (106) 106
human genetics (102) 102
hunter syndrome (100) 100
medical research (97) 97
young adult (95) 95
hematopoietic stem cells (93) 93
hurler-syndrome (93) 93
brain (91) 91
medicine, experimental (90) 90
heparan sulfate (89) 89
mice, knockout (89) 89
biotechnology & applied microbiology (88) 88
lysosomal storage disorders (88) 88
mice, inbred c57bl (86) 86
mucopolysaccharidosis i - therapy (86) 86
mucopolysaccharidosis ii - metabolism (86) 86
brain - metabolism (84) 84
neurosciences (84) 84
physiological aspects (84) 84
genetic aspects (82) 82
infant, newborn (82) 82
mucopolysaccharidosis ii - pathology (80) 80
mucopolysaccharidosis ii - diagnosis (79) 79
genetic therapy (78) 78
mucopolysaccharidosis i - genetics (77) 77
lysosomes - metabolism (75) 75
brain - pathology (74) 74
expression (73) 73
hunter-syndrome (73) 73
alpha-l-iduronidase (71) 71
multidisciplinary sciences (71) 71
pathology (71) 71
fibroblasts (70) 70
stem cells (70) 70
biology (69) 69
gene expression (68) 68
hematopoietic stem cell transplantation (67) 67
identification (67) 67
mucopolysaccharidosis i - metabolism (67) 67
pharmacology (67) 67
lysosomal storage (66) 66
biopharmaceutics (65) 65
lysosomes - enzymology (65) 65
iduronate sulfatase - genetics (64) 64
molecular biology (64) 64
maroteaux-lamy-syndrome (63) 63
patients (63) 63
central nervous system (62) 62
central-nervous-system (62) 62
gene (62) 62
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1613) 1613
French (13) 13
Spanish (6) 6
Chinese (4) 4
German (4) 4
Portuguese (4) 4
Japanese (3) 3
Polish (3) 3
Italian (2) 2
Russian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Molecular Therapy, ISSN 1525-0016, 05/2018, Volume 26, Issue 5, pp. 1366 - 1374
Mucopolysaccharidosis II (MPS II) is an X-linked recessive lysosomal storage disease caused by mutations in the iduronate-2-sulfatase ( ) gene. Since IDS... 
blood-brain barrier | glycosaminoglycans | enzyme replacement therapy | iduronate-2-sulfatase | mucopolysaccharidosis II | lysosomal storage disease | transferrin receptor | HUMAN INSULIN-RECEPTOR | MEDICINE, RESEARCH & EXPERIMENTAL | 6-PHOSPHATE RECEPTOR | PRIMATE | RHESUS-MONKEYS | MONOCLONAL-ANTIBODY | REDUCES GLYCOSOAMINOGLYCANS | HUNTER-SYNDROME | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | DISEASE | GENETICS & HEREDITY | IDURONIDASE | ENZYME REPLACEMENT THERAPY | Cell Line | Tissue Distribution - drug effects | Antibodies, Monoclonal - pharmacology | Humans | Antibodies, Monoclonal - pharmacokinetics | Blood-Brain Barrier - drug effects | Receptor, IGF Type 2 - metabolism | Recombinant Fusion Proteins | Blood-Brain Barrier - metabolism | Mice, Knockout | Brain - drug effects | Brain - metabolism | Receptor, IGF Type 2 - genetics | Animals | Mucopolysaccharidosis II - metabolism | Antibodies, Monoclonal - administration & dosage | Mucopolysaccharidosis II - drug therapy | Fibroblasts - drug effects | Mucopolysaccharidosis II - genetics | Mice | Receptors, Transferrin - antagonists & inhibitors | Disease Models, Animal | Fibroblasts - metabolism | Heparan sulfate | Brain | Enzymes | Transferrin | Animal models | Intravenous administration | Glycosaminoglycans | Statistical analysis | Lysosomal storage diseases | Mucopolysaccharidosis | Monkeys & apes | Experiments | Neurological diseases | Proteins | Blood-brain barrier | Fibroblasts | Fusion protein | Drug dosages | Binding sites | Original
Journal Article
Journal Article
Osteoarthritis and Cartilage, ISSN 1063-4584, 2013, Volume 21, Issue 12, pp. 1813 - 1823
Summary Background Mucopolysaccharidoses (MPSs) are rare genetic diseases caused by a deficient activity of one of the lysosomal enzymes involved in the... 
Rheumatology | Osteoimmunology | Dysostosis multiplex | Mucopolysaccharidosis | Metabolic inflammation | anti-TNF | ISOFLAVONE EXTRACT | STORAGE DISEASE | GENISTEIN-MEDIATED INHIBITION | BONE-MARROW-TRANSPLANTATION | HURLER-DISEASE | JOINT DISEASE | RHEUMATOLOGY | GLYCOSAMINOGLYCAN SYNTHESIS | FELINE MODEL | GROWTH-PLATE | ORTHOPEDICS | ENZYME REPLACEMENT THERAPY | Synovitis - metabolism | Mucopolysaccharidosis VI - immunology | Mucopolysaccharidosis VII - metabolism | Mucopolysaccharidoses - metabolism | Humans | Mucopolysaccharidosis VI - complications | Bone Diseases - metabolism | Mucopolysaccharidoses - immunology | Bone Diseases - etiology | Mucopolysaccharidosis II - metabolism | Cartilage, Articular - metabolism | Dysostoses - metabolism | Synovitis - etiology | Synovitis - immunology | Mucopolysaccharidoses - complications | Joint Diseases - immunology | Mucopolysaccharidosis I - metabolism | Glycosaminoglycans - metabolism | Joint Diseases - metabolism | Glycosaminoglycans - immunology | Dysostoses - immunology | Bone Diseases - immunology | Mucopolysaccharidosis I - complications | Mucopolysaccharidosis II - complications | Mucopolysaccharidosis I - immunology | Joint Diseases - etiology | Mucopolysaccharidosis VI - metabolism | Mucopolysaccharidosis VII - immunology | Mucopolysaccharidosis II - immunology | Mucopolysaccharidosis VII - complications | Cartilage, Articular - immunology | Dysostoses - etiology | Enzymes | Medical colleges | Inflammation | Glycosaminoglycans | Medical genetics
Journal Article
PLoS ONE, ISSN 1932-6203, 01/2012, Volume 7, Issue 1, p. e30341
A major challenge for the treatment of many central nervous system (CNS) disorders is the lack of convenient and effective methods for delivering biological... 
MUCOPOLYSACCHARIDOSIS-II | TRANSFERRIN RECEPTOR | MULTIDISCIPLINARY SCIENCES | ADENOASSOCIATED VIRUS VECTOR | CENTRAL-NERVOUS-SYSTEM | MONOCLONAL-ANTIBODY | II HUNTER-SYNDROME | CEREBROSPINAL-FLUID | BLOOD-BRAIN-BARRIER | ENZYME REPLACEMENT THERAPY | GROWTH FACTOR-II/MANNOSE-6-PHOSPHATE RECEPTOR | Immunohistochemistry | Recombinant Proteins - therapeutic use | Neurons - pathology | Oligodendroglia - metabolism | Central Nervous System - metabolism | Iodine Radioisotopes | Spinal Cord - drug effects | Spinal Cord - metabolism | Species Specificity | Humans | Central Nervous System - pathology | Macaca fascicularis | Recombinant Proteins - pharmacokinetics | Positron-Emission Tomography | Tissue Distribution | Lysosomes - metabolism | Mucopolysaccharidosis II - metabolism | Oligodendroglia - drug effects | Spinal Cord - pathology | Mucopolysaccharidosis II - genetics | Iduronate Sulfatase - administration & dosage | Neurons - metabolism | Neurons - drug effects | Injections, Spinal | Recombinant Proteins - administration & dosage | Mice, Knockout | Oligodendroglia - pathology | Enzyme Replacement Therapy - methods | Animals | Mucopolysaccharidosis II - drug therapy | Dogs | Central Nervous System - drug effects | Iduronate Sulfatase - genetics | Mice | Iduronate Sulfatase - therapeutic use | Enzymes | Biological products | Gene therapy | Neurons | Brain | Nuclear medicine | Spinal cord | Drug delivery systems | Intravenous administration | Glycosaminoglycans | Central nervous system | Medical services | Parenchyma | Lysosomes | Mucopolysaccharidosis | Insulin-like growth factors | Cerebrospinal fluid | Molecular weight | Proteins | Biological effects | Rodents | Animal tissues | Oligodendrocytes | Primates | Recombinant | Medical instruments | Insulin | Biological activity | Hospitals | Algorithms | Storage | Biological warfare | Alzheimers disease
Journal Article
Scientific Reports, ISSN 2045-2322, 2015, Volume 5, Issue 1, p. 9378
Journal Article
Analytical and Bioanalytical Chemistry, ISSN 1618-2642, 2/2017, Volume 409, Issue 5, pp. 1425 - 1433
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2016, Volume 11, Issue 5, p. e0156452
Lysosomal Storage Disorders (LSDs) are a group of metabolic syndromes, each one due to the deficit of one lysosomal enzyme. Many LSDs affect most of the organ... 
HUNTER-SYNDROME | TRANSPORT | THERAPY | DISEASES | DRUG-DELIVERY | INFLAMMATION | CONVECTION | MULTIDISCIPLINARY SCIENCES | BARRIER | CENTRAL-NERVOUS-SYSTEM | MOUSE MODELS | Albumins - chemistry | Fluorescein-5-isothiocyanate - pharmacokinetics | Nanoparticles - chemistry | Polylactic Acid-Polyglycolic Acid Copolymer | Polyglycolic Acid - pharmacology | Drug Carriers - chemistry | Lactic Acid - pharmacokinetics | Mucopolysaccharidosis II - pathology | Fluorescein-5-isothiocyanate - chemistry | Mucopolysaccharidosis II - metabolism | Nanoparticles - therapeutic use | Mucopolysaccharidosis II - genetics | Lactic Acid - pharmacology | Disease Models, Animal | Mucopolysaccharidosis I - metabolism | Fluorescein-5-isothiocyanate - pharmacology | Lactic Acid - chemistry | Mucopolysaccharidosis I - pathology | Drug Carriers - pharmacology | Blood-Brain Barrier - metabolism | Mice, Knockout | Enzyme Replacement Therapy - methods | Albumins - pharmacokinetics | Albumins - pharmacology | Animals | Polyglycolic Acid - pharmacokinetics | Mucopolysaccharidosis II - drug therapy | Mucopolysaccharidosis I - drug therapy | Polyglycolic Acid - chemistry | Mucopolysaccharidosis I - genetics | Drug Carriers - pharmacokinetics | Mice | Metabolism, Inborn errors of | Nanoparticles | Enzymes | Blood-brain barrier | Analysis | Albumin | Research | Health aspects | Therapy | Pediatrics | Animal models | Drug delivery systems | Disease | Biodegradability | Central nervous system | Disorders | Lysosomal storage diseases | Nervous system | Mucopolysaccharidosis | Neurosurgery | Molecular weight | Polylactide-co-glycolide | Biomedical materials | Low molecular weights | Rodents | Biocompatibility | Life sciences | Biodegradation | Phenotypes | Brain research | Storage | Acids | Womens health | Neurological complications | Metabolic disorders | Apoptosis
Journal Article
Journal Article
Molecular Genetics and Metabolism, ISSN 1096-7192, 11/2016, Volume 119, Issue 3, pp. 232 - 238
Journal Article